PMID- 33466125
OWN - NLM
STAT- MEDLINE
DCOM- 20210203
LR  - 20230905
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 2
DP  - 2021 Jan 15
TI  - Renshen (Panax ginseng) and Huanglian (Rhizoma Coptidis) For T2DM: A protocol of 
      systematic review and meta-analysis of randomized clinical trials.
PG  - e23743
LID - 10.1097/MD.0000000000023743 [doi]
LID - e23743
AB  - INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a metabolic disease 
      characterized by high blood sugar caused by impaired insulin action. With an 
      increasing incidence year by year, it has become a worldwide epidemic. Because of 
      its serious, long-term condition, T2DM has a bad impact on the life and 
      well-being of individuals, families and society. Renshen and Huanglian or 
      compound prescription contain Renshen and Huanglian for treatment of T2DM has 
      already been confirmed. However, due to the lack of evidence, there is no 
      specific method or suggestion, so it is necessary to carry out systematic 
      evaluation on Renshen and Huanglian and provide effective evidence for further 
      research. METHODS AND ANALYSIS: We will search English databases (PubMed, Embase, 
      Web of Science, Nature, Science on line, the Cochrane Library) and Chinese 
      databases (CNKI, Wan Fang, VIP, Chinese biomedical database), from the 
      establishment of database to October 2020, for randomized controlled trials 
      (RCTs) of ginseng and coptis and the compound containing ginseng and coptis in 
      the treatment of T2DM. Primary outcomes: fasting blood-glucose (FBG), 2 Hours 
      Postprandial Blood Glucose (2hPBG), Glycosylated hemoglobin A1c (HbA1c). 
      Additional outcomes: Low Density Lipoprotein (LDL), High Density Lipoprotein 
      (HDL), triglycerides (TG), total serum cholesterol (TC). Two researchers 
      independently extracted the data and evaluated the quality of the included 
      research, and meta-analysis was conducted on the included data using the software 
      of RevMan5.3 and Stata V.12.0. RESULTS: The results of this study will 
      systematically evaluate the effectiveness and safety of Renshen and Huanglian 
      intervention for people with T2DM. CONCLUSION: The systematic review of this 
      study will summarize the current published evidence of Renshen and Huanglian or 
      compound prescription contain Renshen and Huanglian for the treatment of T2DM, 
      which can further guide the promotion and application of it. ETHICS AND 
      DISSEMINATION: This study is a systematic review; the outcomes are based on the 
      published evidence, so examination and agreement by the ethics committee are not 
      required in this study. We intend to publish the study results in a journal or 
      conference presentations. OPEN SCIENCE FRAMEWORK OSF REGISTRATION NUMBER: October 
      18, 2020. osf.io/8gz7c (https://osf.io/8gz7c).
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Wang, Shengnan
AU  - Wang S
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ichuan.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Yue, Rensong
AU  - Yue R
AUID- ORCID: 0000-0002-4417-3312
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ichuan.
FAU - Huang, Xiaoying
AU  - Huang X
AUID- ORCID: 0000-0002-4599-8869
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ichuan.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Li, Linzhi
AU  - Li L
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ichuan.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Xu, Chenyi
AU  - Xu C
AD  - Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ichuan.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu.
FAU - Liu, Longyan
AU  - Liu L
AD  - GuangXi University of Chinese Medicine, Nanlin, Guangxi, China.
LA  - eng
GR  - No.81774279/National Natural Science Foundation of China/
GR  - No.2018SZ0068/The Key Research and Development Project of Sichuan Province/
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Lipids)
RN  - 0 (huanglian)
SB  - IM
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin/drug effects
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Life Style
MH  - Lipids/blood
MH  - *Panax
MH  - Randomized Controlled Trials as Topic
MH  - Research Design
MH  - Meta-Analysis as Topic
MH  - Systematic Review as Topic
PMC - PMC7808494
COIS- All authors involved in this work have no conflicts of interest.
EDAT- 2021/01/21 06:00
MHDA- 2021/02/04 06:00
PMCR- 2021/01/15
CRDT- 2021/01/20 01:05
PHST- 2020/11/10 00:00 [received]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2021/01/20 01:05 [entrez]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2021/02/04 06:00 [medline]
PHST- 2021/01/15 00:00 [pmc-release]
AID - 00005792-202101150-00008 [pii]
AID - MD-D-20-11112 [pii]
AID - 10.1097/MD.0000000000023743 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Jan 15;100(2):e23743. doi: 
      10.1097/MD.0000000000023743.